MarketMoodz
Rhythm's EMANATE misses endpoints; pivot to next-gen MC4R drugs
Rhythm Pharmaceuticals' EMANATE Phase 3 readout for setmelanotide missed its primary endpoints, prompting a strategic shift toward next-gen MC4R programs. The company signaled continued data analysis and a push into bivamelagon and RM-718, plus exploration of SRC1 (NCOA1) and POMC pathways, as investors weigh the implications amid fierce GLP-1 competition.
Key Takeaways
- EMANATE failed to meet primary endpoints in the Phase 3 trial of setmelanotide.
- TRANSCEND data show a 18.8% placebo-adjusted BMI reduction at 52 weeks across all patients.
- Rhythm plans to pursue next-gen MC4R assets bivamelagon and RM-718 and explore SRC1 (NCOA1) and POMC pathways.
- No new safety signals; safety profile remains consistent with prior studies.
- After-hours stock reaction: shares down 4.98% to $86.00.
People Involved
- No specific individuals mentioned
Entities Involved
- Rhythm Pharmaceuticals, Inc.Biotech company developing MC4R obesity therapies
- TRANSCEND studyPhase 3 clinical trial program for setmelanotide
- DAYBREAK trialPhase 2 trial exploring MC4R agonism
MarketMoodz Analysis
The readout reinforces a pivot away from the current EMANATE program toward next-gen MC4R assets, with investors watching for deal activity and timeline updates. The 18.8% placebo-adjusted BMI difference at 52 weeks provides a benchmark for what future MC4R programs must achieve to gain traction in a crowded obesity-drug landscape dominated by GLP-1/GIP therapies and other MC4R efforts.
Historically, MC4R-based obesity drugs have struggled to translate modest biomarker signals into durable, approvable endpoints amid competitive pressure. Rhythm's pivot toward bivamelagon, RM-718, and SRC1/POMC pathways mirrors a broader industry shift toward more robust efficacy signals and combination strategies. Near-term catalysts include data readouts, potential partnering discussions, and any re-sourcing of late-stage trials.
Source: Original Article